MarketPulse
E

$EMBC

5 articles found
2 positive
1 negative
2 neutral
The Motley FoolThe Motley Fool··Keith Noonan

Embecta Stock Crashes 57.8% on Weak Q2 Earnings, Slashed Guidance

Embecta plummeted 57.8% after missing earnings and revenue targets in fiscal Q2 2026, with management sharply reducing full-year guidance.
EMBCearnings missguidance reduction
BenzingaBenzinga··Globe Newswire

Embecta Initiates Quarterly Dividend, Signals Confidence in Insulin Delivery Business

Embecta initiates quarterly $0.01-per-share dividend payable June 2026, signaling financial stability and shareholder capital return confidence.
EMBCdividendcash dividend
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Embecta Gears Up for Q2 2026 Earnings as Insulin Delivery Leader Faces Market Pressures

Embecta Corp. (EMBC) schedules May 5, 2026 earnings call to discuss Q2 2026 results and operational updates amid competitive insulin delivery market pressures.
EMBCconference callinvestor relations
BenzingaBenzinga··Vandana Singh

Embecta Expands Drug-Delivery Portfolio With $200M Owen Mumford Acquisition

Embecta to acquire UK firm Owen Mumford for up to $200M, bolstering drug-delivery capabilities and chronic care market reach. Stock rises 4.63%.
EMBCacquisitionM&A
BenzingaBenzinga··Na

Embecta to Acquire UK Drug-Delivery Specialist Owen Mumford for Up to £150M

Embecta agrees to acquire Owen Mumford Holdings for up to £150M, diversifying beyond insulin delivery into broader drug-delivery technologies.
EMBCacquisitionmanufacturing